首页>
外国专利>
Predictive test of the selection of patients with metastatic breast cancer for combination therapy and hormone therapy
Predictive test of the selection of patients with metastatic breast cancer for combination therapy and hormone therapy
展开▼
机译:选择转移性乳腺癌患者进行联合治疗和激素治疗的预测测试
展开▼
页面导航
摘要
著录项
相似文献
摘要
A mass-spectral method is disclosed for determining whether a breast cancer patient is likely to benefit from administration of a combination treatment in the form of a targeted anti-cancer drug in addition to an endocrine therapy drug. The method obtains a mass spectrum from a blood-based sample from the patient. The spectrum is subject to one or more predefined pre-processing steps. Values of selected features in the spectrum at one or more predefined m/z ranges are obtained. The values are used in a classification algorithm using a training set comprising class-labeled spectra a class label for the sample is obtained. If the class label is Poor, the patient is identified as being likely to benefit from the combination treatment. In a variation, the Poor class label predicts whether the patient is unlikely to benefit from endocrine therapy drugs alone, regardless of the patient's HER2 status.
展开▼